A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
Clinical trial NCT03255382 · COMPLETED
Trial details
- NCT number
- NCT03255382
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-22
- Primary completion
- 2018-07-06
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.